

Application Serial No. 09910,009
Amendment dated 12 September 2003
Reply to Office Action mailed 12 March 2003

AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions, including listings, of claims in the application.

Listing of Claims

Claim 1 (currently amended): An isolated peptide comprising the amino acid sequence Xaa-Asn-Cys-Cys-Asn-Gly-Gly-Cys-Ser-Ser-Lys-Xaa-Cys-Arg-Asp-His-Ala-Arg-Cys-Cys (SEQ ID NO:211), wherein Xaa at position 1 is Gln or pyro-Glu and Xaa at position 12 is Trp or bromo-Trp ~~selected from the group consisting of:~~

- (a) ~~a peptide set forth in Table 1 or Table 2 and~~
- (b) ~~a derivative of the peptide in (a).~~

Claim 2 (currently amended): The isolated peptide of claim 1, wherein ~~Xaa₁ is Glu, Xaa₂ Xaa~~ at position 1 is pyro-Glu, Xaa₄ and Xaa at position 12 is Trp and Xaa₃ is Tyr.

Claims 3-8 (canceled).

Claim 9 (currently amended): An isolated μ -conopeptide propeptide ~~having an~~ comprising the amino acid sequence Gly-Ser-Met-Met-Ser-Lys-Leu-Gly-Val-Leu-Leu-Thr-Val-Cys-Leu-Leu-Leu-Phe-Pro-Leu-Thr-Ala-Leu-Pro-Leu-Asp-Gly-Asp-Gln-Pro-Ala-Asp-Arg-Pro-Ala-Glu-Arg-Met-Gln-Asp-ASp-Ile-Ser-Ser-Asp-Glu-His-Pro-Leu-Phe-Asp-Lys-Arg-Gln-Asn-Cys-Cys-Asn-Gly-Gly-Cys-Ser-Ser-Lys-Trp-Cys-Arg-Asp-His-Ala-Arg-Cys-Cys-Gly-Arg (SEQ ID NO:210) ~~set forth in Table 1.~~

Claim 10 (currently amended): A method for treating or preventing disorders associated with voltage gated ~~ion~~ neuronal sodium channel disorders in which comprises administering to a patient

Application Serial No. 09910,009
Amendment dated 12 September 2003
Reply to Office Action mailed 12 March 2003

in need thereof a therapeutically effective amount of a peptide of claim 1 or a pharmaceutically acceptable ~~acceptable~~ salt thereof.

Claim 11 (original): The method of claim 10, wherein said disorder is a neurologic disorder.

Claim 12 (original): The method of claim 11, wherein said neurologic disorder is Amyotrophic Lateral Sclerosis.

Claim 13 (original): The method of claim 11, wherein said neurologic disorder is head trauma.

Claim 14 (original): The method of claim 11, wherein said neurologic disorder is epilepsy.

Claim 15 (original): The method of claim 11, wherein said neurologic disorder is a neurotoxic injury associated with conditions of hypoxia, anoxia or ischemia.

Claim 16 (original): The method of claim 15, wherein said neurotoxic injury is associated with stroke, cerebrovascular accident, brain or spinal cord trauma, myocardial infarct, physical trauma, drownings, suffocation, perinatal asphyxia, or hypoglycemic events.

Claim 17 (original): The method of claim 10, wherein said disorder is pain.

Claim 18 (original): The method of claim 17, wherein said pain is migraine, acute pain, persistent pain, chronic pain, neuropathic pain or nociceptive pain.

Claim 19 (currently amended): The method of claim 18, wherein the pain is phantom limb pain, neuroma pain or pain associated with trigeminal neuralgia, diabetic neuropathy, and post-herpetic neuralgia, ~~neuroma pain, phantom limb pain.~~

Application Serial No. 09910,009
Amendment dated 12 September 2003
Reply to Office Action mailed 12 March 2003

Claim 20 (original): The method of claim 17, wherein said pain is burn pain.

Claim 21 (canceled).

Claim 22 (currently amended): The method of claim 10 ~~21~~, wherein said ~~neuromuscular~~ disorder is myofacial pain syndrome, chronic muscle spasm, ~~dystonias~~ or spasticity.

Claim 23 (canceled).

Claim 24 (currently amended): A method of alleviating pain which comprises administering to a mammal that is either exhibiting pain or is about to be subjected to a pain-causing event a pain-alleviating amount of a peptide of claim 1 or a pharmaceutically acceptable ~~acceptable~~ salt thereof.

Claim 25 (original): The method of claim 24, wherein the peptide is administered as a local anesthetic.

Claim 26 (original): The method of claim 24, wherein the peptide is administered as an ocular anesthetic.

Claims 27-42 (canceled).